Navigation Links
Plastics that convert light to electricity could have a big impact
Date:8/4/2009

Researchers the world over are striving to develop organic solar cells that can be produced easily and inexpensively as thin films that could be widely used to generate electricity.

But a major obstacle is coaxing these carbon-based materials to reliably form the proper structure at the nanoscale (tinier than 2-millionths of an inch) to be highly efficient in converting light to electricity. The goal is to develop cells made from low-cost plastics that will transform at least 10 percent of the sunlight that they absorb into usable electricity and can be easily manufactured.

A research team headed by David Ginger, a University of Washington associate professor of chemistry, has found a way to make images of tiny bubbles and channels, roughly 10,000 times smaller than a human hair, inside plastic solar cells. These bubbles and channels form within the polymers as they are being created in a baking process, called annealing, that is used to improve the materials' performance.

The researchers are able to measure directly how much current each tiny bubble and channel carries, thus developing an understanding of exactly how a solar cell converts light into electricity. Ginger believes that will lead to a better understanding of which materials created under which conditions are most likely to meet the 10 percent efficiency goal.

As researchers approach that threshold, nanostructured plastic solar cells could be put into use on a broad scale, he said. As a start, they could be incorporated into purses or backpacks to charge cellular phones or mp3 players, but eventually they could make in important contribution to the electrical power supply.

Most researchers make plastic solar cells by blending two materials together in a thin film, then baking them to improve their performance. In the process, bubbles and channels form much as they would in a cake batter. The bubbles and channels affect how well the cell convert
'/>"/>

Contact: Vince Stricherz
vinces@u.washington.edu
206-543-2580
University of Washington
Source:Eurekalert  

Page: 1 2 3

Related biology technology :

1. Gerresheimer Sells Technical Plastics Business
2. Bio-Tec Environmental Introduces Their New Plastic Additive Showing 45% Biodegradation of Plastics in Just 14 Days
3. Gerresheimer Starts Process to Sell off its Business Segment of Technical Plastics
4. Pure Plastics Pitch Proves Perfect
5. PharmAthene, Inc. Closes on $19.3 Million Private Placement of Convertible Notes and Common Stock Warrants
6. Novavax Announces Repayment of $5 Million of Convertible Debt
7. Viral Genetics Retires Nearly $3.5 Million Convertible Debt and Provides Updates on Capital Structure and Stock Issuances
8. Verenium Completes Amendment to 8% Senior Convertible Notes
9. First step to converting solar energy using artificial leaf
10. Schering-Plough Declares Quarterly Dividends on Common Shares and Mandatory Convertible Preferred Stock
11. Wyeth Announces Holder Right to Surrender Convertible Debentures
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Plastics that convert light to electricity could have a big impact
(Date:7/30/2015)... HIGHLIGHTS:Q2 2015 Results (all changes ... Reported sales were $697 million compared to $701 million ... by 8%, and changes in foreign currency exchange rates ... 1%. , By business unit, organic sales growth ... in SAFC Commercial. , Reported diluted EPS was ...
(Date:7/29/2015)... 2015 Sanofi, un leader ... résultats pour le premier semestre 2015. Le Directeur ... Visionner l,interview vidéo et lire la ... Au sommaire de l,interview :  ... croissance - Diabète - ...
(Date:7/29/2015)...  HealthSouth Corporation (NYSE: HLS ), ... healthcare services, offering both facility-based and home-based post-acute ... the second quarter ended June 30, 2015. ... volume growth in both segments and an 11.0% ... President and Chief Executive Officer of HealthSouth. "While ...
(Date:7/29/2015)... , July 29, 2015  AmnioChor Inc., an early ... is very pleased to announce that the Musculoskeletal Transplant ... agreed to invest in their seed round of development ... tissue storage capabilities. AmnioChor,s technology allows ... the human stem cells living within those tissues. Amnion ...
Breaking Biology Technology:Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20HealthSouth Reports Results for Second Quarter 2015 2HealthSouth Reports Results for Second Quarter 2015 3HealthSouth Reports Results for Second Quarter 2015 4HealthSouth Reports Results for Second Quarter 2015 5HealthSouth Reports Results for Second Quarter 2015 6HealthSouth Reports Results for Second Quarter 2015 7HealthSouth Reports Results for Second Quarter 2015 8HealthSouth Reports Results for Second Quarter 2015 9HealthSouth Reports Results for Second Quarter 2015 10HealthSouth Reports Results for Second Quarter 2015 11HealthSouth Reports Results for Second Quarter 2015 12HealthSouth Reports Results for Second Quarter 2015 13HealthSouth Reports Results for Second Quarter 2015 14HealthSouth Reports Results for Second Quarter 2015 15HealthSouth Reports Results for Second Quarter 2015 16HealthSouth Reports Results for Second Quarter 2015 17
... , , , ... ANDS ) today announced finalization of the protocol for the Company,s ... in hepatitis C patients. Allowance of the protocol has been received ... is expected to commence within the next several weeks. , , ...
... , , GAITHERSBURG, Md. , ... new program to evaluate the use of non-animal methods to replace ... The is the first program of its kind and demonstrates the ... , , IIVS was an integral part ...
... 30 /PRNewswire-FirstCall/ - Medicago Inc. (TSX-V: MDG) a biotechnology ... based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), ... with its vaccine candidate for the Influenza A (H1N1) ... a single dose of 5 micrograms induced a positive ...
Cached Biology Technology:Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients 2Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients 3Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients 4Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients 5IIVS Announces Initiation by EPA of a Pilot Program to Evaluate Non-Animal Eye-Irritation Methods 2Medicago's H1N1 pandemic vaccine candidate shows positive response in 100% of vaccinated animals after a single dose 2Medicago's H1N1 pandemic vaccine candidate shows positive response in 100% of vaccinated animals after a single dose 3
(Date:7/31/2015)... SHENZHEN , Chine, 31 juillet 2015 /PRNewswire/ ... (ICG-10, www.icg-10.org ) sera organisée par le ... Shenzhen en Chine. ... année. Depuis son inauguration en 2006, l,ICG est ... influentes dans le domaine des « omiques » et c,est ...
(Date:7/30/2015)... Calif. , July 30, 2015 ... services for gene function analysis and biomarker discovery, ... RNA (sgRNA) Knockout Library targeting all human protein ... and permanently "knock out" a gene,s function. Cellecta,s ... a high throughput screening tool so that researchers ...
(Date:7/21/2015)... , July 21, 2015 Today, ZTE announced ... received as well as expected revenues in 2015 that relate to ... communicated revenue guidance of approximately 2,200 MSEK for 2015. ... a leading smartphone manufacturer in China and ... 02 5 for Axon , ...
Breaking Biology News(10 mins):La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 3CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2
... 221.10.254.64 FRAX is a computer-based algorithm developed by ... Diseases to help predict the 10-year risk of fragility ... being used increasingly by physicians around the world to ... of a clinical assessment. In a newly published ...
... the Centers for Disease Control and Prevention, 25 percent ... 5,000 steps a day) and 75 percent do not ... activity each week and muscle-strengthening activity twice a week) ... of Missouri researchers contend that physical inactivity is the ...
... cover 71% of our planet, with over half with ... is still very limited, we know that the deep ... high biodiversity, and harbors important biological and mineral resources. ... in the potential for biodiversity loss and, with this, ...
Cached Biology News:New IOF-ISCD review clarifies the use of FRAX in clinical practice 2New IOF-ISCD review clarifies the use of FRAX in clinical practice 3Even with regular exercise, people with inactive lifestyles more at risk for chronic diseases 2Man and the last great wilderness: Human impact on the deep sea 2Man and the last great wilderness: Human impact on the deep sea 3Man and the last great wilderness: Human impact on the deep sea 4
Incomplete Adjuvant...
... Lacks the mycobacteria found ... side-effects. For this reason, Incomplete, ... Freund's Adjuvants may be used to produce water-in-oil ... emulsions stimulate high and long-lasting antibody responses which ...
2,4-Dinitrophenyl hapten is conjugated to Human Serum Albumin (HSA) protein through lysine....
HiTrap Streptavidin HP, 5 x 1 ml. Category: Chromatography Systems & Accessories, Systems....
Biology Products: